Amyris Inc (NASDAQ:AMRS) COO Eduardo Alvarez acquired 11,877 shares of the stock in a transaction on Wednesday, September 5th. The shares were purchased at an average price of $8.45 per share, for a total transaction of $100,360.65. Following the completion of the transaction, the chief operating officer now owns 331,877 shares in the company, valued at approximately $2,804,360.65. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

NASDAQ AMRS traded down $0.07 on Friday, hitting $8.22. 807,134 shares of the stock were exchanged, compared to its average volume of 1,179,053. Amyris Inc has a 52-week low of $2.71 and a 52-week high of $9.22. The company has a debt-to-equity ratio of -0.24, a quick ratio of 0.38 and a current ratio of 0.42. The stock has a market cap of $417.55 million, a price-to-earnings ratio of -2.70 and a beta of 0.20.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.08). The business had revenue of $24.81 million for the quarter, compared to analysts’ expectations of $37.52 million. During the same quarter last year, the firm posted ($1.32) EPS. The business’s quarterly revenue was down 3.4% on a year-over-year basis. research analysts forecast that Amyris Inc will post -1.41 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Amyris during the 1st quarter valued at $110,000. Rhumbline Advisers purchased a new position in shares of Amyris during the 2nd quarter valued at $147,000. Renaissance Technologies LLC purchased a new position in shares of Amyris during the 2nd quarter valued at $167,000. Element Capital Management LLC purchased a new position in shares of Amyris during the 1st quarter valued at $227,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Amyris during the 2nd quarter valued at $292,000. Institutional investors and hedge funds own 27.90% of the company’s stock.

Several research firms have weighed in on AMRS. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the stock a “buy” rating in a research report on Thursday, August 30th. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. BidaskClub upgraded shares of Amyris from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Finally, ValuEngine upgraded shares of Amyris from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Amyris currently has a consensus rating of “Buy” and an average price target of $9.13.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Featured Article: How Do I Invest in Dividend Stocks

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.